WAYNE, Pa.--(BUSINESS WIRE)--Nov. 30, 2015--
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
technologies for critical care and surgery, is committed to connecting
clinicians with technology in a way that improves clinical practice and
advances patient outcomes. Teleflex will attend the GAVeCeLT conference
in Milan, Italy on December 1-3, 2015.
GAVeCeLT is an Italian Scientific Group doing research on Long Term
Vascular Access. The GAVeCeLT society has played a fundamental role over
the years in driving adoption of best practices in vascular access.
The GAVeCeLT society invited Dr. Leonardo Lorente to present a cost
analysis study related to the use of antimicrobial catheters. Following
his studies issued in 20141,2, he has further documented, in
an additional research published in 2015, the ability of the
Arrow® Central Venous Catheter (CVC) with ARROWg+ard Blue® Technology to
reduce both catheter-related bloodstream infections (CRBSIs) and direct
costs associated with treating those infections, even when the infection
risk is already low.3 The study was an independent
retrospective analysis performed and published by Leonardo Lorente,
M.D., Ph.D., and colleagues. Dr. Lorente works in the Department of
Critical Care at Hospital Universitario de Canarias, in Tenerife, Spain.
During the event, Teleflex will highlight its range of innovative
solutions for intraosseous and central vascular access. This includes
the Arrow® EZ-IO® Intraosseous Vascular Access System, the ARROWg+ard
Blue Plus® Pressure Injectable CVC and the Arrow® PICC with Chlorag+ard®
Technology.
The Arrow® EZ-IO® Intraosseous Vascular Access System from Teleflex is a
complete solution for rapid vascular access – whether the emergency
responder is facing difficult vascular access challenges or the need for
fast intraosseous access for critical situations and life-threatening
emergencies. This system is designed to provide the medical professional
vascular access to the central circulation within seconds, delivering
medications, fluids and blood products to adult and pediatric patients
alike.
Chlorag+ard® Technology is the 3rd generation of chlorhexidine-based
protective treatment for Arrow® Catheters. The application of
Chlorag+ard® Technology uses a proprietary process whereby chlorhexidine
is chemically bonded to the catheter surface providing a controlled
release. Both the internal and external catheter surfaces are treated
with chlorhexidine protection. Chlorag+ard® Technology provides an
initial burst of chlorhexidine with a sustained release resulting in
antithrombogenic and antimicrobial protection.
Another featured product will be the ARROWg+ard Blue Plus® Pressure
Injectable CVC. Many patients who receive a central line will require a
CT scan and 100% need protection from infection. So to streamline
patient care, the ARROWg+ard Blue Plus® Pressure Injectable CVC performs
three vital functions: helping prevent catheter-related blood stream
infections, delivering therapy and pressure-injecting contrast for CT.
We invite all participants to our booth during the days to learn about
our latest technologies.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson
RCI®, LMA®, Pilling®, Rüsch®
and Weck® – trusted brands united by a common sense of
purpose.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, the Teleflex logo, Arrow, ARROWg+ard Blue, ARROWg+ard Blue
Plus, Chlorag+ard, Deknatel, EZ-IO, Hudson RCI, LMA, Pilling, Rüsch, and
Weck are trademarks of Teleflex Incorporated or its affiliates, in the
U.S. and/or other countries. © 2015 Teleflex Incorporated. All rights
reserved.
References:
-
Lorente L, Lecuona M, Jiménez A, et al. Chlorhexidine-silver
sulfadiazine-impregnated venous catheters save costs. American Journal
of Infection Control, 2014; 42: 321-324.
-
Lorente L, Lecuona M, Jiménez A, et al. Cost/benefit analysis of
chlorhexidine-silver sulfadiazine-impregnated venous catheters for
femoral access. American Journal of Infection Control, 2014; 42:
1130-1132.
-
Lorente L, Lecuona M, Jiménez A, et al. Efficiency of
chlorhexidine-silver sulfadiazine-impregnated venous catheters at
subclavian sites. American Journal of Infection Control, 2015.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151130005871/en/
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836
or
Martina
Teichmann-Zindler
Director Marketing Communications International
+49
(0)7151-406-538
martina.teichmann@teleflex.com